Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2019, Vol. 41 ›› Issue (5): 696-701.doi: 10.3881/j.issn.1000-503X.11097

• Review Articles • Previous Articles     Next Articles

Immunotherapy of Gastrointestinal Stromal Tumors

ZHU Changzhen,LIU Dong,KANG Weiming()   

  1. Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
  • Received:2018-12-14 Online:2019-10-30 Published:2019-11-08
  • Contact: Weiming KANG
  • Supported by:
    Supported by the Heathcock-Hawson Cancer Research Fund(Y-HS2019-43);Wu Jieping Medical Fund


Gastrointestinal stromal tumors(GISTs)are the most common mesenchymal tumors of the gastrointestinal tract and respond poorly to conventional radiochemotherapy.Complete excision is the only possible way to cure GISTs.Although targeted therapy is effective for GISTs,multiple and/or secondary mutations of KIT or PDGFRA gene have lead to increased drug resistance and disease relapse.A variety of tumor infiltrating immune cells and complex immune microenvironments have been found in GISTs.Many immune cells participate in the occurrence and development of GISTs and play key roles in targeted therapy.The feasibility and effectiveness of immunotherapy for GISTs have been well demonstrated in preclinical and clinical studies.

Key words: gastrointestinal stromal tumors, immunotherapy, immune checkpoint suppression, chimeric antigen receptor T-cell immunotherapy

CLC Number: